Myriad Asset Management Ltd. acquired a new stake in shares of Qiagen N.V. (NASDAQ:QGEN) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 150,688 shares of the company’s stock, valued at approximately $4,747,000. Myriad Asset Management Ltd. owned about 0.07% of Qiagen at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Qiagen by 4.6% during the 2nd quarter. BlackRock Inc. now owns 8,203,013 shares of the company’s stock valued at $275,048,000 after purchasing an additional 363,377 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Qiagen by 7.0% during the 2nd quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock valued at $202,986,000 after purchasing an additional 394,201 shares during the last quarter. Frontier Capital Management Co. LLC lifted its holdings in shares of Qiagen by 0.7% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 2,554,021 shares of the company’s stock valued at $80,452,000 after purchasing an additional 17,946 shares during the last quarter. State Street Corp lifted its holdings in shares of Qiagen by 2.1% during the 2nd quarter. State Street Corp now owns 2,330,061 shares of the company’s stock valued at $78,130,000 after purchasing an additional 48,679 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Qiagen by 0.8% during the 3rd quarter. Legal & General Group Plc now owns 1,909,956 shares of the company’s stock valued at $52,573,000 after purchasing an additional 15,660 shares during the last quarter. Hedge funds and other institutional investors own 62.37% of the company’s stock.

QGEN has been the subject of several analyst reports. Zacks Investment Research lowered Qiagen from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a report on Wednesday, November 8th. TheStreet upgraded Qiagen from a “c+” rating to a “b+” rating in a report on Tuesday, November 7th. Commerzbank reiterated a “buy” rating on shares of Qiagen in a report on Tuesday, November 7th. Finally, Cowen restated a “hold” rating and issued a $33.00 target price on shares of Qiagen in a research note on Friday, November 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. Qiagen presently has an average rating of “Hold” and a consensus target price of $34.06.

Qiagen N.V. (NASDAQ:QGEN) opened at $30.84 on Thursday. The stock has a market capitalization of $7,062.02, a price-to-earnings ratio of 25.22, a P/E/G ratio of 1.90 and a beta of 1.10. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78. Qiagen N.V. has a 52 week low of $27.51 and a 52 week high of $36.34.

Qiagen (NASDAQ:QGEN) last issued its earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.32. The company had revenue of $364.00 million during the quarter, compared to analyst estimates of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the business posted $0.29 EPS. analysts forecast that Qiagen N.V. will post 1.25 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/07/myriad-asset-management-ltd-acquires-new-holdings-in-qiagen-n-v-qgen.html.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Institutional Ownership by Quarter for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.